Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis Posts 28 Percent Spike in Q1 Sales, Expects More Deals in 2001

NEW YORK, May 14 – Comparative genomics company Exelixis of South San Francisco, Calif., said Monday its first quarter revenues increased 28 percent to $7.7 million as milestone payments rose from collaborations with companies including Bayer, Pharmacia, and Bristol Myers Squibb.

Looking ahead, Exelixis said it expects to close three new corporate collaborations with pharmaceutical and agricultural partners sometime during the remainder of the year. The company also expects to achieve revenue growth of 10 to 15 percent in the second quarter compared with the first quarter. Expenses are forecast to rise by 20 to 25 percent from first quarter levels.

In the first quarter, the company’s operating expenses rose to $22.1 million from $13.2 million in the first quarter as research and development expenses and general and administrative expenses increased.

Exelixis’ net losses widened to $9.8 million, or 22 cents a share, excluding non-cash charges for stock compensation expense and amortization of goodwill and intangibles, compared with net losses of $4.0 million, or 14 cents a share, excluding non-cash charges.

At the end of the quarter, Exelixis had cash and cash equivalents totaling $108 million, down from $112.6 million at the end of December.

During the quarter, Exelixis acquired Artemis Pharmaceuticals, a German company that has developed vertebrate model systems technologies, and formed a strategic alliance with AVI BioPharma for antisense drug discovery research and development.

Also in the first quarter, Exelixis delivered targets to some of its partners, including insecticide targets to Bayer and Alzheimer’s targets to Pharmacia.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.